Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET..

Ann Oncol. 2015 Oct;26(10):2007-9. doi: 10.1093/annonc/mdv334. Epub 2015 Aug 11.

Authors

G V Scagliotti¹, M Di Maio²

Affiliations

¹ Department of Oncology, University of Torino at San Luigi Gonzaga Hospital, Orbassano, Turin, Italy [email protected].
² Department of Oncology, University of Torino at San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

PMID: 26265168
DOI: 10.1093/annonc/mdv334

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / metabolism
Drug Therapy, Combination
Erlotinib Hydrochloride / therapeutic use*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / metabolism
Prognosis
Proto-Oncogene Proteins c-met / antagonists & inhibitors*
Pyrrolidinones / therapeutic use*
Quinolines / therapeutic use*

Substances

ARQ 197
Antineoplastic Agents
Pyrrolidinones
Quinolines
Erlotinib Hydrochloride
MET protein, human
Proto-Oncogene Proteins c-met